Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 00:32 | 2026-02-17 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | Officer | SELL | $7.38 | 847 | $6,253 | 51,080 |
| 2026-02-19 00:01 | 2026-02-15 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Francis Richard D | Officer | OPT+S | $34.22 | 447,778 | $15,324,799 | 605,771 |
| 2026-02-18 20:59 | 2026-02-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $58.00 | 100 | $5,800 | 450,044 |
| 2026-02-18 00:05 | 2026-02-12 | CLYM | Climb Bio, Inc. | Thomas Stephen Basil | Director | SELL | $5.29 | 100,000 | $529,130 | 204,657 |
| 2026-02-18 00:38 | 2026-02-13 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $102.09 | 2,000 | $204,180 | 0 |
| 2026-02-18 00:22 | 2026-02-17 | ZTS | Zoetis Inc. | PECK KRISTIN C | Director, Officer | OPT+S | $127.05 | 20,000 | $2,540,964 | 101,337 |
| 2026-02-18 00:04 | 2026-02-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $76.80 | 500 | $38,400 | 69,329 |
| 2026-02-18 00:08 | 2026-02-12 | ANIP | Ani Pharmaceuticals Inc. | Mutz Christopher | Officer | SELL | $76.55 | 7,032 | $538,300 | 92,566 |
| 2026-02-18 05:20 | 2026-02-17 | IRON | Disc Medicine, Inc. | Khara Rahul | Officer | SELL | $62.86 | 2,853 | $179,340 | 52,173 |
| 2026-02-18 05:03 | 2026-02-17 | IRON | Disc Medicine, Inc. | Quisel John D | Director, Officer | SELL | $62.86 | 13,264 | $833,775 | 226,064 |
| 2026-02-18 05:05 | 2026-02-17 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Officer | SELL | $62.86 | 3,231 | $203,101 | 54,324 |
| 2026-02-18 05:09 | 2026-02-17 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $62.86 | 3,256 | $204,672 | 92,589 |
| 2026-02-18 05:14 | 2026-02-10 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% owner | BUY | $0.50 | 4,000,000 | $2,000,000 | 6,779,440 |
| 2026-02-18 05:15 | 2026-02-17 | IRON | Disc Medicine, Inc. | Stephenson Pamela | Officer | SELL | $62.86 | 5,531 | $347,679 | 80,998 |
| 2026-02-18 04:28 | 2026-02-12 | OCUL | OCULAR THERAPEUTIX, INC | Waheed Nadia | Officer | SELL | $9.04 | 7,863 | $71,082 | 318,417 |
| 2026-02-18 04:29 | 2026-02-12 | OCUL | OCULAR THERAPEUTIX, INC | Dugel Pravin | Director, Officer | SELL | $9.04 | 124,882 | $1,128,933 | 3,033,078 |
| 2026-02-18 04:30 | 2026-02-12 | OCUL | OCULAR THERAPEUTIX, INC | Nayak Sanjay | Officer | SELL | $9.04 | 10,348 | $93,546 | 332,412 |
| 2026-02-18 04:31 | 2026-02-12 | OCUL | OCULAR THERAPEUTIX, INC | Notman Donald | Officer | SELL | $9.04 | 11,446 | $103,472 | 366,356 |
| 2026-02-18 03:26 | 2026-02-13 | ALNY | Alnylam Pharmaceuticals Inc. | Poulton Jeffrey V. | Officer | SELL | $310.08 | 2,242 | $695,201 | 59,802 |
| 2026-02-18 03:26 | 2026-02-13 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | SELL | $321.25 | 4,000 | $1,284,980 | 21,264 |
| 2026-02-18 03:27 | 2026-02-13 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $310.08 | 1,959 | $607,448 | 31,769 |
| 2026-02-18 03:27 | 2026-02-13 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | SELL | $310.08 | 6,958 | $2,157,542 | 85,662 |
| 2026-02-18 03:28 | 2026-02-13 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | SELL | $310.08 | 2,242 | $695,201 | 24,848 |
| 2026-02-18 02:56 | 2026-02-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $27.59 | 417 | $11,505 | 44,089 |
| 2026-02-18 01:24 | 2026-02-17 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $32.37 | 7,000 | $226,559 | 34,018 |
| 2026-02-18 00:32 | 2026-02-17 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $474.68 | 50 | $23,734 | 220 |
| 2026-02-14 00:30 | 2026-02-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Officer | SELL | $32.87 | 8,000 | $262,965 | 146,981 |
| 2026-02-14 00:27 | 2026-02-11 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | Director, Officer | OPT+S | $16.00 | 400 | $6,400 | 14,954 |
| 2026-02-14 00:26 | 2026-02-11 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | OPT+S | $16.00 | 400 | $6,400 | 156,052 |
| 2026-02-14 01:35 | 2026-02-11 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | BUY | $22.50 | 25,985 | $584,663 | 347,968 |
| 2026-02-14 01:06 | 2026-02-12 | ZBIO | Zenas BioPharma, Inc. | Allen Patricia L | Director | BUY | $25.16 | 19,860 | $499,745 | 19,860 |
| 2026-02-14 00:37 | 2026-02-11 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $65.93 | 1,000 | $65,930 | 41,048 |
| 2026-02-14 05:00 | 2026-02-11 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Director | SELL | $26.64 | 1,225,784 | $32,658,563 | 15,127,329 |
| 2026-02-14 05:02 | 2026-02-11 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Director | SELL | $26.64 | 1,225,784 | $32,658,563 | 15,127,329 |
| 2026-02-14 04:45 | 2026-02-11 | ROIV | Roivant Sciences Ltd. | QVT Financial LP | SELL | $26.64 | 1,225,784 | $32,658,563 | 15,127,329 | |
| 2026-02-14 03:40 | 2026-02-11 | IONS | IONIS PHARMACEUTICALS INC | PARSHALL B LYNNE | Director | SELL | $82.72 | 5,000 | $413,589 | 56,344 |
| 2026-02-14 03:40 | 2026-02-13 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | SELL | $81.76 | 15,642 | $1,278,913 | 32,105 |
| 2026-02-14 03:25 | 2026-02-12 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $27.93 | 20,404 | $569,808 | 44,089 |
| 2026-02-14 00:05 | 2026-02-11 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $54.00 | 10,000 | $540,000 | 12,835 |
| 2026-02-14 00:05 | 2026-02-12 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $15.70 | 3,354 | $52,658 | 428,286 |
| 2026-02-13 17:23 | 2026-02-11 | APLS | Apellis Pharmaceuticals Inc. | DeLong Mark Jeffrey | Officer | SELL | $22.15 | 368 | $8,153 | 114,591 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Andrews Patricia S | Director | BUY | $0.86 | 35,400 | $30,292 | 78,128 |
| 2026-02-13 15:00 | 2026-02-11 | ONCY | ONCOLYTICS BIOTECH INC | Aromando Andrew | Officer | BUY | $0.86 | 29,600 | $25,418 | 55,100 |
| 2026-02-13 15:00 | 2026-02-11 | ONCY | ONCOLYTICS BIOTECH INC | Seizinger Bernd R. | Director | BUY | $0.83 | 100,000 | $83,450 | 566,991 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Hagerman Allison | Officer | BUY | $0.83 | 10,000 | $8,298 | 115,059 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Brown Deborah Margaret | Director | BUY | $0.85 | 25,000 | $21,240 | 109,851 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Heineman Thomas Charles | Officer | BUY | $0.83 | 12,132 | $10,033 | 282,818 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Pisano Wayne | Director | BUY | $0.84 | 30,000 | $25,338 | 492,414 |
| 2026-02-13 15:00 | 2026-02-12 | ONCY | ONCOLYTICS BIOTECH INC | Look Kirk | Officer | BUY | $0.84 | 12,000 | $10,104 | 287,515 |
| 2026-02-13 15:00 | 2026-02-11 | ONCY | ONCOLYTICS BIOTECH INC | Kelly Jared | Director, Officer | BUY | $0.84 | 35,100 | $29,519 | 109,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.